Achieve Life Sciences (ACHV) Earning Somewhat Positive Press Coverage, Accern Reports

Media coverage about Achieve Life Sciences (NASDAQ:ACHV) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Achieve Life Sciences earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7985804084285 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Separately, ValuEngine upgraded Achieve Life Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Achieve Life Sciences traded down $1.69, reaching $5.26, during midday trading on Thursday, Marketbeat.com reports. The company had a trading volume of 4,542 shares, compared to its average volume of 29,201. Achieve Life Sciences has a fifty-two week low of $6.77 and a fifty-two week high of $62.70.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($2.40) EPS for the quarter.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Insider Buying and Selling by Quarter for Achieve Life Sciences (NASDAQ:ACHV)

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply